This renders TUBA1C a promising therapeutic target whose suppression can potentially reverse the immunosuppressive tumor microenvironment, delay cancer progression, improve the response to ICB treatment, and prolong the survival of ccRCC patients. Here, TUBA1C is linked to cancer.